Author:
Song Fuyu,Zheng Xin,Wang Yujia,Chow Shein-Chung,Sun Hongqiang
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Biosimilars. U.S. Food and Drug Administration. Available online: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. Published 2021. (Accessed on June 15, 2021)
2. Kirchhoff C, Wang X, Conlon H, Anderson S, Ryan A, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–705. https://doi.org/10.1002/bit.26438.
3. U.S. Food and Drug Administration. BIOSIMILARS ACTION PLAN: Balancing Innovation and Competition (p.1). US Food & Drug Administration, 2018. Available online on: https://www.fda.gov/media/114574/download (Accessed on June 15, 2021)
4. Tu C, Wang Y, Hu T, Hsu L. Analysis of pharmacokinetic and pharmacodynamic parameters in EU- versus US-licensed reference biological products: are in vivo bridging studies justified for biosimilar development? BioDrugs. 2019;33(4):437–46. https://doi.org/10.1007/s40259-019-00357-2.
5. Dillingh M, Reijers J, Malone K et al. Clinical evaluation of Humira® biosimilar ONS-3010 in healthy volunteers: focus on pharmacokinetics and pharmacodynamics. Front Immunol 2016, 7. https://doi.org/10.3389/fimmu.2016.00508
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献